Effects of Intravenous Immunoglobulin on HIV Viremia
Author Information
Author(s): Tomas Mellberg, Veronica D. Gonzalez, Annica Lindkvist, Arvid Edén, Anders Sönnerborg, Johan K. Sandberg, Bo Svennerholm, Magnus Gisslén
Primary Institution: University of Gothenburg, Sahlgrenska University Hospital
Hypothesis
Does high dosage intravenous immunoglobulin (IVIG) treatment have a long-term effect on residual viremia and T-lymphocyte activation in HIV-infected patients on effective antiretroviral therapy?
Conclusion
The decrease in the latent HIV-1 pool observed during IVIG treatment is transient, with residual viremia rebounding to pre-treatment levels after 48-104 weeks.
Supporting Evidence
- Plasma residual viremia rebounded to pre-treatment levels after IVIG treatment.
- Six out of nine patients had detectable levels of plasma HIV-RNA at follow-up.
- A correlation between plasma HIV-1 RNA and CD4+ T-cell count was found.
Takeaway
This study looked at how a treatment called IVIG affects the amount of HIV in the blood. It found that while the treatment worked for a little while, the HIV levels went back up after some time.
Methodology
Nine HIV-infected subjects on effective ART were evaluated 48-104 weeks after IVIG treatment, along with 14 HIV-infected controls on suppressive ART. Plasma HIV-1 RNA was analyzed using an ultrasensitive PCR method.
Potential Biases
The study did not mention specific risks of bias.
Limitations
The study had a small sample size and was not powered for detection of existing possible correlations.
Participant Demographics
Participants included 9 HIV-infected subjects on effective ART and 14 HIV-infected controls, with a mix of ages and genders.
Statistical Information
P-Value
0.0036
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website